Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy

Li, Ji; Zhao, Ming; Liang, Wendi; Wu, Siwen; Wang, Zheran; Wang, Dongkai

doi:10.1016/j.jconrel.2022.01.015

Cited by 17 publications

(12 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al constructed tumor growth factor β small interference RNA (siTGF-β) and SHK co-delivery nanoparticles for TNBC chemo-immunotherapy. 123 SHKinduced ICD exhibited a positive tumor inhibitory effect. Effective silencing of TGF-β by siTGF-β suppressed EMT, promoted CTL infiltration, inhibited regulatory T lymphocytes proliferation, and suppressed lung metastasis.…”

Section: Lipid-polymer Hybrid Nanoparticlesmentioning

confidence: 89%

Promising Nanomedicines of Shikonin for Cancer Therapy

Yan¹,

Li²,

Sun³

et al. 2023

IJN

View full text Add to dashboard Cite

Malignant tumor, the leading cause of death worldwide, poses a serious threat to human health. For decades, natural product has been proven to be an essential source for novel anticancer drug discovery. Shikonin (SHK), a natural molecule separated from the root of Lithospermum erythrorhizon, shows great potential in anticancer therapy. However, its further clinical application is significantly restricted by poor bioavailability, adverse effects, and non-selective toxicity. With the development of nanotechnology, nano drug delivery systems have emerged as promising strategies to improve bioavailability and enhance the therapeutic efficacy of drugs. To overcome the shortcoming of SHK, various nano drug delivery systems such as liposomes, polymeric micelles, nanoparticles, nanogels, and nanoemulsions, were developed to achieve efficient delivery for enhanced antitumor effects. Herein, this review summarizes the anticancer pharmacological activities and pharmacokinetics of SHK. Additionally, the latest progress of SHK nanomedicines in cancer therapy is outlined, focusing on long circulation, tumor targeting ability, tumor microenvironment responsive drug release, and nanosystem-mediated combination therapy. Finally, the challenges and prospects of SHK nanomedicines in the future clinical application are spotlighted.

show abstract

Section: Lipid-polymer Hybrid Nanoparticlesmentioning

confidence: 89%

Promising Nanomedicines of Shikonin for Cancer Therapy

Yan¹,

Li²,

Sun³

et al. 2023

IJN

View full text Add to dashboard Cite

show abstract

“…145 In another study, Li et al constructed a codelivery system, combined with TGF-β small interference RNA (siTGF-β) and shikonin, where they observed that shikonin effectively induced ICD, which led to DC maturation and further significantly enhanced cytotoxic T lymphocyte response, resulting in tumor suppression. The shikonin/ siTGF-β NPs had a strong therapeutic effect, with a higher inhibition of lung metastasis in breast cancer, eliciting long- term immunological memory response and thereby preventing tumor recurrence 146 (Figure 9).…”

Section: Cancer Immunity Cyclementioning

confidence: 99%

Phytochemical-Based Nanomedicine for Targeting Tumor Microenvironment and Inhibiting Cancer Chemoresistance: Recent Advances and Pharmacological Insights

Sa,

Mohapatra,

Swain

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Cancer remains the leading cause of death and rapidly evolving disease worldwide. The understanding of disease pathophysiology has improved through advanced research investigation, and several therapeutic strategies are being used for better cancer treatment. However, the increase in cancer relapse and metastatic-related deaths indicate that available therapies and clinically approved chemotherapy drugs are not sufficient to combat cancer. Further, the constant crosstalk between tumor cells and the tumor microenvironment (TME) is crucial for the development, progression, metastasis, and therapeutic response to tumors. In this regard, phytochemicals with multimodal targeting abilities can be used as an alternative to current cancer therapy by inhibiting cancer survival pathways or modulating TME. However, due to their poor pharmacokinetics and low bioavailability, the success of phytochemicals in clinical trials is limited. Therefore, developing phytochemical-based nanomedicine or phytonanomedicine can improve the pharmacokinetic profile of these phytochemicals. Herein, the molecular characteristics and pharmacological insights of the proposed phytonanomedicine in cancer therapy targeting tumor tissue and altering the characteristics of cancer stem cells, chemoresistance, TME, and cancer immunity are well discussed. Further, we have highlighted the clinical perspective and challenges of phytonanomedicine in filling the gap in potential cancer therapeutics using various nanoplatforms. Overall, we have discussed how clinical success and pharmacological insights could make it more beneficial to boost the concept of nanomedicine in the academic and pharmaceutical fields to counter cancer metastases and drug resistance.

show abstract

“…Shikonin is found to be a potential inhibitor in pancreatic cancer as it mediates PD-L1 degradation which in turn suppresses immune evasion in pancreatic cancer cells via NF-κB/STAT3 and NF-κB/CSN5 signaling pathway ( Ruan et al, 2021 ). The anticancer potential of shikonin co delivered with siTGF-β against triple negative breast cancer cells was investigated by Li et al and this co-delivery approach was found to be magnificently efficacious for the same ( Li et al, 2022 ). In a nutshell, shikonin/alkannin and their derivatives are promising candidates for anticancer activity which act by various signaling pathways.…”

Section: Pharmacological Activitiesmentioning

confidence: 99%